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Open access under CC BY license.Glossary
Adjuvant: A molecule that is added to a vaccine to amplify the immune
response against the antigen. Mineral oil (Freund’s adjuvant), aluminium
hydroxide and, more recently, monophosphoryl lipid A (MPLA) have been
used as adjuvants. Only MPLA functions via TLR4.
Cysteine-rich capping region: The conserved leucine residues that form the
hydrophobic core of the first and the last leucine-rich repeat (LRR) are shielded
from solvent exposure by cysteine-rich capping regions at the N- and the
C-terminus of the LRR domain. They are referred to as LRRNT and LRRCT,
respectively. In TLRs, the LRRNT is a b-hairpin stabilized by a single disulfide
bond, the LRRCT adopts an a-b fold containing two disulfides.
Juxtamembrane region: The extracytoplasmic region located upstream and in
proximity of the transmembrane region. In TLRs, the juxtamembrane region
refers to the C-terminal cysteine-rich capping region (LRRCT).
Leucine-rich repeat (LRR): A short sequence of about 24 residues in TLRs in
which leucine residues occupy conserved positions that are buried to form the
hydrophobic core of the protein. Each repeat adopts a short b-strand and a
loop conformation that might contain elements of secondary structure. LRR
sequences are repeated throughout the extracytoplasmic domain of TLRs and
form a solenoid tertiary structure (i.e. a coil) with a parallel b-sheet on the
concave side and variable structural features on the lateral and the convex
sides, which influence the degree of curvature of the protein. LRR motifs
contain surface exposed residues that are highly variable, which makes it a
versatile motif for recognition of vast array of ligands and diverse protein-
protein contacts.TLR4 is unique among pathogen-recognition receptors
in that it initiates different pathways in different cellular
locations. Binding of a bridging factor, Mal, allows re-
cruitment of an adapter protein, MyD88, at the plasma
membrane, which leads to the production of proinflam-
matory cytokines. Upon internalization, TLR4 uses a
different bridging factor, TRAM, to activate a MyD88-
independent pathway that results in type I interferon
expression. Interestingly, both Mal and TRAM are local-
ised initially at the plasma membrane. In this Opinion, I
suggest a possible mechanism by which endosomal
acidification triggers the differential adaptor usage of
TLR4. I discuss the evidence of the pH sensitivity of TLR4
and propose a new dimerisation mode for TLR4 based on
the crystal structure of the related receptor TLR3 bound
to its ligand, double-stranded RNA.
TLR signalling
Toll-like receptors (TLRs) are key regulators of the innate
immune response to pathogens. They recognize signature
molecules that are crucial for the integrity of the microor-
ganism and distinguishable from self either by their chem-
ical composition or by their cellular localisation (Fig. 1) [1].
For example, viral and bacterial nucleic acids are picked
upon in endolysosomal compartments but not in the cyto-
plasm or the extracellular space of the host. This is
achieved by the nucleic acid-binding subgroup of TLRs
(TLR3, TLR7, TLR8 and TLR9) that are expressed only
intracellularly. In contrast, microbial cell wall components
such as lipopolysaccharides (LPS), lipopeptides and flagel-
lar proteins are recognized at the plasma membrane of
immune and epithelial cells by TLR4, TLR2 and TLR5,
respectively. Ligand binding to TLRs is the first event in a
signalling process that allows defences to be put in place for
clearance of the infection and for long-term protection via
the molecular memory of the adaptive immunity.
TLRs are type I membrane receptors (see Glossary) with
extracytoplasmic domains (ectodomains) responsible for
ligand binding. These domains contain versatile leucine-
rich repeats (LRRs) that mediate binding and form a right-
handed superhelix that extends throughout the domain
and adopts the shape of a horseshoe. TLR4 is the only TLR
that requires a co-receptor to bind a ligand; the co-receptor
is a small lipid-binding glycoprotein known as myeloid
differentiation factor 2 (MD-2). In addition to LPS, TLR4Corresponding author: Gangloff, M. (mg308@cam.ac.uk).
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well as endogenous or exogenous proteins, in the presence
or absence of MD-2 [2].
Signalling downstream of TLRs is initiated by either
homodimerisation or heterodimerisation of the receptor;
for example, TLR3 and TLR4 form homodimers, whereas
TLR2 forms heterodimers with TLR1 or TLR6 [3]. Ligand
binding induces a crosslinking of the ectodomains, which in
turn causes the intracellular signalling domains of the
receptors to be brought in close proximity. The signalling
domain comprises the Toll-IL-1 receptor (TIR) domain,
which is present also in the intracellular adaptor proteins
MyD88 and TRIF, and their bridging factors Mal (also
known as TIRAP) and TRAM [4]. These adapters and
bridging factors are platforms that organize downstream
signalling. TIR domains do not possess enzymatic activity
but function via protein-protein interactions to recruit cel-
lular kinases that activate specific transcription factors. As
individual TIR domains do not have detectable affinity for
each other, it is likely that the assembly of the signalling
complex triggers the juxtaposition of multiple TIR domains
in order to increase affinity by a crowding effect [5].
MyD88 is attracted to the activated receptors via its
C-terminal TIR domain. This adaptor is used by all TLRs,Type I membrane receptors: The type refers to the position of the N-terminus
of the protein. Type I membrane receptors such as TLRs have an extra-
cytoplasmic N-terminus and are anchored to the lipid membrane by a single-
pass transmembrane a-helix.
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Figure 1. TLR signalling. There are two types of TLRs, those located at the plasma membrane that sense microbial membrane components and the intracellular ones that
sense microbial nucleic acids. TLR4 can signal both at the plasma membrane and at endosomes, where it can be activated by viral envelope glycoproteins. All TLRs signal
via the adaptor MyD88, except TLR3 that can function only via TRIF. MyD88 leads to the activation of kinases such as IL-1 receptor-associated kinases (IRAKs). The resulting
phosphorylation cascade activates members of TNF receptor associated factor 6 (TRAF6) and, ultimately, transcription factors NF-kB, JNK and p38 (as well as IRF7 for TLR7
and TLR9). The TRIF pathway stimulates TRAF6, Fas-associated protein with death domain (FADD) and the transcription factors IRF3, IRF7, NF-kB. TLR4 is the only receptor
that can engage both MyD88-dependent and -independent pathways. It requires bridging adaptors TRAM and Mal to recruit MyD88 and TRIF, respectively. TLR2 depends
only partially on Mal. Membrane signalling triggers an inflammatory response whereas intracellular TLR signalling leads to antiviral and adjuvant responses.
Opinion Trends in Biochemical Sciences March 2012, Vol. 37, No. 3except TLR3. Engagement of MyD88 initiates polymerisa-
tion of its N-terminal death domain (DD) into a left-handed
helical structure made of six to eight subunits of MyD88, 4
subunits of the IL-1-receptor-associated kinase (IRAK)4,
and four molecules of either IRAK1 or IRAK2. This supra-
molecular assembly is referred to as the myddosome [6,7].
In contrast to the TIR interactions, the assembly of DDs
forms a stable complex. The DD signalling tower, in turn,
leads to auto-phosphorylation or cross-phosphorylation of
IRAKs, activation of TNF-receptor-associated factor
(TRAF)6 and, subsequently, activation of nuclear factor
(NF)-kB and mitogen-activated protein kinases (MAPKs).
For TLR7 and TLR9, IRAK1 can also stimulate interferon-
regulatory factor IRF7 to produce IFNa. By contrast, TLR3
exclusively recruits the adaptor TRIF (also known as
TICAM1) via its TIR domain. TRIF possesses different
protein interaction motifs that allow recruitment of TRAF6
and the protein kinases TBK1 and RIPK1, which in turn
leads to the activation of another adaptor, Fas-associated
protein with death domain (FADD), as well as the tran-
scription factors NF-kB, IRF3 and IRF7, respectively.Once more, TLR4 stands out compared to other
members of the TLR family in that it initiates both
MyD88-dependent and MyD88-independent pathways.
This is achieved by using the bridging factors Mal and
TRAM [8–12], respectively, at different times and locations
(Figure 1) [13]. Initial binding of Mal allows TLR4 recruit-
ment of MyD88 at the plasma membrane and signalling
within a few minutes [14]. About half an hour later, TLR4 is
translocated away from the plasma membrane, where
TRAM is believed to help recruit TRIF at endolysosomes
[13,15]. Both Mal and TRAM are subjected to tight regula-
tory controls by phosphorylation [16]. This provides extra
control on the TLR4 signalling pathway and gives cellular
context to the response elicited by a given ligand. Interest-
ingly, both adaptors are localised at the plasma membrane
via a phosphatidyl-inositol-4,5-bisphosphate (PIP2) binding
motif for Mal [14] and a myristoyl anchor for TRAM, respec-
tively [17]. Only TRAM shuffles between the cell membrane
and endosomal vesicles, where it induces signalling. In this
Opinion, I propose that TLR4 adopts different conforma-
tions in the two cellular locations, and that this feature93
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location.
An alternative dimerisation mode for TLR4
The initial observation that led to this article was the
comparison of the m-shaped crystal structures of the ecto-
domains of the TLR3 dimer, the TLR2-TLR1 or TLR2-
TLR6 heterodimers, and the TLR4 dimer, when bound
to their respective ligands. Whereas the TLR4 homodimer
and the TLR2 heterodimers adopt a vertical structure, the
TLR3 homodimer is tilted (Figure 2a,b). Could this varia-
tion in tilt angle contribute to the observed functional(a)
(c)
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Figure 2. TLR ectodomains form m-shaped dimers that are either vertical or tilted. (a) T
code 3FXI) forms a vertical dimer. (b) When bound to their ligand (double-stranded RNA
TLR3 ectodomains occupy similar spaces despite their different length and degree of cu
dimer arranged in a TLR3-like tilted conformation was built in PyMol by superimposi
superposition was achieved by using chain B of a second copy of 3FXI (3FXI2) onto cha
intact. Supplementary Table S1 and Supplementary Figure S2 show that the primary bin
by chains A and C from 3FXI1 and chains B and D from 3FXI2 (coordinates are availab
94differences in adaptor recruitment? Remarkably, the
TLR4-MD-2-LPS complex was prepared at pH 7.5 [18],
whereas the TLR3 complex was purified and crystallized at
pH 5.5 (Supplementary Table S1) [19]. Because a crystal
structure is a snapshot of a given molecular state in a well-
defined environment, could the acidification of the TLR4
complex trigger the adoption of a tilted conformation simi-
lar to that reported for TLR3?
To try to answer this question, I used the molecular
visualisation software Pymol [20] to generate in silico an
arrangement of the TLR4-MD-2 complex that was similar
to that of the TLR3 complex (Figure 2c,d). The coordinatesB
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he crystal structure of the complex formed by TLR4, MD-2 and LPS at pH 7.5 (PDB
) at acidic pH, TLR3 dimers are tilted (PDB code 3CIY). (c) Superimposed TLR4 and
rvature. TLR4 is shown in black and TLR3 in cyan and green. (d) A TLR4-MD-2-LPS
ng receptor chain A of a first copy of 3FXI (3FXI1) onto chain A of 3CIY. Another
in B of the previous 3CIY. The primary interface between TLR4 and MD-2 was left
ding site between TLR4 and MD-2 is pH-independent. The new dimer was produced
le as Supplementary Material).
Opinion Trends in Biochemical Sciences March 2012, Vol. 37, No. 3of this hypothesized TLR4-MD-2-LPS model are available
as a PDB file in the Supplementary Material. Despite the
TLR4 ectodomain being about 70 residues and two LRRs
shorter than that of TLR3, both molecules occupied similar
spaces because of their different degree of curvature
(Figure 2c). In this in silico-generated complex, the
TLR4 dimer presents the same tilt-angle as TLR3, and
MD-2 cross-links TLR4 chains in a manner that is less
compact than the crystal structure and reminiscent of a
model proposed by Kim et al. (Supplementary Figure S1)
[21]. Interestingly, the N-linked glycosylations in TLR3
and TLR4, as well as LPS in the case of TLR4, were
required for the superposition to generate a model without
major atomic clashes. The structure of the TLR3 dimer and
that of the in silico-generated TLR4 superimpose with an
rmsd of 5.40 A˚ over 6440 atoms.
The alternative dimerisation site on TLR4 is located at
the juxtamembrane region and involves the C-terminal
LRR21 and the cysteine-rich capping region LRRCT. Im-
portantly, the tilted ectodomains bring their C-termini
closer together, with the a carbons of Cys627 about 6 A˚
apart instead of 22 A˚. The size of the dimerisation surface
in the in silico-generated model (580 A˚2) is similar to that
of the original TLR4 structure (610 A˚2; PDB code 3FXI)
However, the participation of MD-2 in the dimerisation
surface is weaker in the TLR3-derived model (77 A˚2 in-
stead of 470 A˚2), and the interacting residues are different.
Whereas MD-2 interacts with LRR15 to LRR17 in the
original TLR4 structure, it seems to interact with
LRR17 and LRR18 in the TLR3-derived model. Interest-
ingly, the common interface (LRR17) is centred on MD-2
residues Thr84 and Met85, in a region known to undergo
conformational changes upon ligand binding (Supplemen-
tary Figure S2) and to confer constitutive activity in a
species-specific domain-swapping study [22]. In addition,Dimerisation inter
at pH 7.5 (3FXI)
Histidine protonat
at pH < 6.0 and p
shift in the dimeri
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Figure 3. TLR4 contains histidine residues that modify its charge distribution upon end
TLR4-MD-2-LPS crystal structure (PDB code 3FXI) at the dimeric interface. Electropositive
dimerisation site of TLR4 contains five histidine residues that are sensitive to pH chan
potential at the dimer interface. (d) The complex might undergo conformational changthis region is a flexible loop essential for the transfer of LPS
from CD14 to monomeric MD-2 and for TLR4 activation at
the cell surface [23].
A more detailed analysis revealed features that validate
the potential quaternary structural rearrangement at
acidic pH. The dimerisation surface of the TLR4-MD-2-
LPS crystal structure appears to contain a high number of
histidine residues. Given that the imidazole ring of histi-
dine has a pKa of 6.1, relatively small shifts in pH can
change the average charge of this residue at physiologically
relevant pH values. Hence, for pH values <6.0, the imid-
azole side-chain is mostly protonated and carries two N-H
bonds with a positive charge. I propose that, in the acidic
endosomes, the introduction of these positive charges leads
to repulsion of the TLR4 chains and triggers an alternative
dimerisation mode, with only one histidine (His587) poten-
tially involved in formation of a salt bridge with Asp614.
In the TLR4 crystal structure, three histidine residues
(His431, His458 and His555) are involved directly in the
interface, and two more are found in the immediate vicini-
ty, His456 and His529. This represents a total of ten
pH-sensitive residues within the dimerisation area
(Figure 3). These histidines are strictly conserved across
mammals, except for His456 and His458, which are specific
to primates. His458 is located at the twofold symmetry axis
of the TLR4 homodimer and forms p-stacking interactions
with its counterpart. It has been suggested that nickel
binding to TLR4 is mediated by His458 and His456 and
leads to receptor activation in the absence of LPS [24].
Alanine scanning and transgenic expression of human
TLR4 in TLR4-deficient mice have confirmed the impor-
tance of these residues in conferring nickel allergy. Impor-
tantly, most of us are not sensitive to nickel. In the light of
my analysis, nickel sensitization could originate at the cell
surface, because intracellular TLR4 would bear protonatedface
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extremely puzzling that MD-2 is required in nickel sensi-
tization, because the key MD-2 residue Phe126 would be
expected to prevent TLR4 dimerisation and subsequent
activation [18,21,25,26]. Therefore, although nickel can
trigger TLR4 signalling in recombinant systems, it is
generally prevented in vivo by an unknown mechanism.
Pathway-specific TLR4 ligands
A growing number of TLR4 ligands, such as allergenic
nickel and the adjuvant monophosphoryl lipid A (MPLA),
are pathway-specific. Whereas Escherichia coli LPS fully
stimulates both pathways, nickel selectively activates the
MyD88-dependent pathway and thus triggers inflamma-
tion and allergy [24]. I have discussed above a potential
mechanism of nickel chelation of TLR4 at the cell surface,
which would explain why nickel cannot elicit TRIF signal-
ing at the acidic endosomes. By contrast, MPLA activates(vii) Intracellular
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(iii) LPS transfer (
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the plasma membrane. Surface signaling involves the myddosome and leads to early N
dependent mechanism. CD14 and TRAM have lipid-raft localization signals and are 
membrane. I propose that, upon endosomal acidification, TLR4 undergoes a conformatio
TIR domains might arrange slightly differently under the curved membrane of the endos
TRAM recruitment. (vii) Endosomal signaling results in the recruitment of TRAM and TR
G from vesicular stomatitis virus VSV), and triggers a delayed NF-kB response. TRIF recr
the lysosome, all endocytosed complexes are targeted for degradation and (ix) antigen
96the TRIF pathway but is unable to trigger MyD88 signal-
ing [27]. MPLA is an LPS derivative that lacks the phos-
phate in position 1 of the lipid-A headgroup and is 100-fold
less toxic than LPS. Why is MPLA unable to activate the
MyD88 pathway? Charge distribution is important for
TLR4 activity [22], and the binding of LPS (which is
negatively charged) creates an attractive force between
TLR4 and MD-2. Therefore, I suggest that this force
may be significantly weaker for MPLA compared to LPS
at the cell surface, whereas the pH-driven conformational
change that I hypothesize for TLR4 in the endosomes
would allow MPLA to signal intracellularly as efficiently
as LPS.
CD14 is essential for intracellular TLR4 signaling
CD14 facilitates LPS transfer from the serum LPS-binding
protein (LBP) to TLR4-MD-2 in a way that enhances, but is
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F-kB activation. (vi) Ligand binding is also required for endocytosis in a dynamin-
engulfed along the TLR4-MD-2-LPS complex. Mal is not translocated out of the
nal change that brings its transmembrane domains closer together. In addition, the
omes, which would lead to a different stacking of the TIR domains that would allow
IF in the case of LPS and MPLA (recruitment of TRAM but not TRIF for glycoprotein
uitment leads to the activation of IRF3, IRF7, NF-kB and FADD, respectively. (viii) In
 presentation.
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mutation that causes CD14 to be produced as a C-terminally
truncated protein, impairs activation of IRF3 in mice [28]. As
the Heedless phenotype can be rescued by overexpression of
soluble CD14, it has been suggested that CD14 enables a
change or participates directly in the supramolecular struc-
ture of TLR4 that allows MyD88-independent signalling
(Figure 4). Therefore, these results support the idea that
TLR4 adopts different conformations at the cell surface and
in the endosomes.
From alternative receptor conformations to selective
adaptor recruitment
Ligand binding leads to TLR4 dimerisation and the clus-
tering of the signalling complexes in specific membrane
microdomains (Figure 4). Whereas Mal targets the com-
plexes to PIP2-rich areas, CD14 directs them to lipid rafts
along with TRAM [13,15]. However, TRAM is not activated
at the cell surface. I suggest that the lack of TRAM signal-
ling at the cell surface can be explained by alternative
conformations of the TLR4 dimers. As described above, at
the acidic pH of the endosomes, the ectodomains might be
tilted and their C-termini could be closer together. Given
that the transmembrane region of TLR4 is separated from
the ectodomain by only four residues [29,30], the confor-
mational change might produce a shift in the transmem-
brane helix which, together with the increased membrane
curvature of the endosomes (compared to that of the plas-
ma membrane at the cell surface), would possibly alter
the association of the cytosolic TIR domains (Figure 4). The
different association of the TIR domains could be the
reason why TRAM is recruited to the receptor complex
in the endosomes and not at the cell surface.
Concluding remarks
This Opinion proposes that the TLR4 dimer might under-
go conformational changes at different cellular locations
due to environmental factors such as pH, the presence of
cell-specific regulators on either sides of the membrane
and the segregation of the signalling components into
membrane microdomains. Different dimerisation modes
might in turn lead to the recruitment of different sets of
adaptors, which determines the signalling output. Fur-
ther work is clearly needed to test this hypothesis. The
effect of pH can be assessed by crystallographic studies in
acidic conditions, or by mutagenesis in which the histidine
residues are changed into positively charged lysines or
arginines to mimic the effect of endosomal acidification.
The intracellular role of CD14 needs to be clarified along
with that of the plethora of TLR4 regulators. Recently, the
crystal structure of the complex formed between MD-1 and
RP105 (a TLR-related molecule) has revealed a different
dimerisation mode of the closest structural homologue of
the TLR4-MD-2 complex [32,33]. More is to be expected
with respect to TLR4 structure and function with the
characterization of non-canonical ligands. Of particular
interest is glycoprotein G from vesicular stomatitis virus
(VSV) that has been shown to trigger a third pathway in
endosomes based on the recruitment of TRAM in the
absence of TRIF [31]. In keeping with this Opinion, the
unusual signalling properties of VSV might be caused by aconformation distinct from that induced by LPS and
MPLA.
TLR4 is a major pharmaceutical target in septic
shock, inflammatory and autoimmune diseases, allergy
and cancer. Anticipating different TLR4 dimerisation
modes might be useful in rational drug design, because
this technique is limited by the difficulty of predicting
major conformational changes in proteins.
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